RE:Roche/Genentech in race for CAR-T therapy in solid tumorsAlthough recent clinical trials have shown greater success in CAR-T cell therapy than conventional treatments in some patients, there are currently three major limitations to CAR-T cell therapy: cell exhaustion, antigen recognition, and prediction of patient response. Together, they explain why CAR-T cell therapy has only been successful in hematological cancers and limited in the treatment of solid tumours, as well as in current use.
Consequentially, the identification of biomarkers is an important consideration because of variability in patient response to CAR-T cells. Patient response to CAR-T cells varies based on factors identified in current scientific literature - some may experience high toxicities and relapse, while others may experience complete remission.
https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=34968084 Repost: SAN DIEGO, Calif. and CALGARY, AB, April 14, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors. The paper, entitled "Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice," was published in Science Translational Medicine in collaboration with researchers at several prestigious institutions, including the Mayo Clinic and Duke University.
---------------------------------------------------------------------
In summary - the efficacy of pelareorep-loaded CAR T cells was augmented when the murine subjects received a subsequent intravenous dose (boost) of pelareorep, and overall demonstrated the ability of pelareorep-loaded CAR T cells to overcome the three most significant barriers to effective CAR T therapy by dramatically increasing CAR T cell persistence, reversing immunosuppressive TMEs, and reducing antigen escape.
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35153543